期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

冠心病心力衰竭患者血清 OPG 和 IGF-Ⅰ水平变化及意义 被引量：2

Changes of Serum Levels of OPG and IGF in Patients with Coronary Heart Disease and Heart Failure
下载PDF
导出
摘要 【目的】探讨冠心病（CHD）心力衰竭患者血清中骨保护素（OPG）和胰岛素样生长因子（IGF-Ⅰ）的水平变化及其意义。【方法】采用酶联免疫吸附检测法测定58例CHD慢性心力衰竭（CHF）患者（CHF组）和22例正常体检者（对照组）血清中OPG与IGF-Ⅰ水平，进行对照分析。【结果】CHF组患者血清OPG水平明显高于正常对照组，且随着心功能的恶化而明显增高（ P＜0．01），而血清IG F-Ⅰ水平明显低于正常对照组，且随着心功能的恶化而明显降低（ P＜0．01）。血清中OPG与IGF-Ⅰ水平呈负相关（ P ＜0．01）。【结论】OPG与IGF-Ⅰ共同参与了CHD的CHF的发生发展过程，二者的血清水平可以作为判断 CHF严重程度的指标。 [Objective]To explore the changes and significance of serum levels of osteoprotegerin （OPG ） and insulin-like growth factor-Ⅰ （IGF-Ⅰ） in patients with chronic heart failure（CHF） and coronary heart dis-ease（CHD） .[Methods]Enzyme-linked immunosorbent assay（ELISA） was used to determine serum levels of OPG and IGF-Ⅰ in 58 patients with CHF and CHD and 22 healthy subjects .Comparative analysis was taken .[Results]Serum OPG in CHF group was obviously higher than that in normal control groups ,and increased with the deterioration of cardiac function obviously （ P 〈0 .01） .Serum IGF-Ⅰin CHF group was obviously lower than that in normal control group ,and decreased with deterioration of cardiac function obviously （ P 〈0 .01） .Serum OPG was negatively related with IGF-Ⅰ（ P〈0 .01） .[Conclusion]OPG and IGF-Ⅰ conjointly participate in the occurrence and development of CHD and heart failure .Serum levels of OPG and IGF-Ⅰ can be used as the indicators for assessing the severity of heart failure .
作者 宿海峰 魏士刚 高山
机构地区 北京延庆县医院心内科
出处 《医学临床研究》 CAS 2014年第4期710-711,714,共3页 Journal of Clinical Research
关键词 冠心病/并发症 心力衰竭/血液 胰岛素样生长因子Ⅰ/血液 Coronary Disease/CO Heart Failure/BL Insulin-Like Grow th Factor I/BL
分类号 R541.4 [医药卫生—心血管疾病]
  • 相关文献

参考文献13

  • 1Simonet WS, Lacey DL, Dunstan CR, et al . Osteoprotegerin: a novel secreted protein involved in the regulation of bone density[J]. Cell ,1997,89(2) :309- 319.
  • 2Hofbauer LC,Khosla S,Dunstan CR, et al . The role of os- teoprotegerin and osteoprotegerin ligand in the paracrine reg- ulation of bone resorption[J]. J Bone Miner Res , 2000, 15 (1) :2-12.
  • 3Browner WS, Lui LY, Cum mings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women[J ]. Clin Endocrinol Metab ,2001,86(2) :631-637.
  • 4Omland T, Drazner MH, Ueland T, et al . Plasma osteoprote gerin levels in the general population:relation to index of left ventricular strueture and funetion[J]. Hypertension , 2007, 49(6) : 1392-1398.
  • 5Thor Ueland, Rune Jemtland, Kristin Godang, et al . Prog- nostic value of osteoprotegerin in heart failure after acute my ocardial infarction[J]. J Am Coll Cardiol , 2004,44 ( 10), 1970-1976.
  • 6Spinale FG, Coker ML, Bond BR, et al. Myocardial matrix degradation and metalloproteinase activation in the failing heart:a potential therapeutic target [J]. Cradiovasc Res, 2000,46 (2) :225-238.
  • 7刘筠,李自普.基质金属蛋白酶及其抑制剂与心肌纤维化的研究进展[J].实用儿科临床杂志,2005,20(8):805-807. 被引量：18
  • 8Spinale FG. Matrix metalloproteinases:regulation and dysreg- ulation in the failing heart [J]. Circ Res , 2002,90 ( 5 ) : 520- 530.
  • 9Yang R, Bunting S, Gillett N, et al. Growth hormone im- proves cardiac performance in experimental heart failure[J]. Circulation , 1995,92(2) : 262-267.
  • 10Akagi Y, Liu W, Zebrowski B, et al . Regulation of vascular endothelial growth factor expression in human colon cancer by insulin like growth factor-1 [J]. Cancer Res , 1998, 58 (17) :4008-4014.

二级参考文献28

  • 1Lombardi R, Betocchi S, Losi MA, et al. Myocardial collagen turnover in hypertrophic cardiomyopathy [ J ]. Circulation, 2003,108(12): 1455 - 1460.
  • 2Taniyama Y, Morishita R, Nakagami H, et al. Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin Ⅱ blockade in cardiomyopathic hamsters[J ]. Circulation, 2000,102(2): 246 - 252.
  • 3Seeland U, Kouchi I, Zolk O, et al. Effect of ranipril and furosemide treatment on interstitial remodeling in post - infarction heart failure rat hesrts[J]. J Mol Cell Cardiol,2002,34(2): 151 - 163.
  • 4Varo N, Iraburu MJ, Varela M, et al. Chronic AT1 blockade stimulates extracellular collagen type Ⅰ degradation and reverses myocardial fibrosis in spontaneously hypertensive rats [J]. Hypertension ,2000,35(6): 1197 - 1202.
  • 5Zannad F, Dousset B, Alla F. Treatment of congestive heart failure: interfering the aldosterone- cardiac extracellular matrix relationship [J]. Hypertension, 2001,38 (5): 1227 - 1232.
  • 6Lijnen PJ, Petrov VV. Role of intracardiac renin - angiotensin - aldosterone system in extracellular matrix remodeling [J]. Methods Find Exp Clin Pharmacol, 2003,25 (7):541 - 564.
  • 7Hayashidani S, Tsutsui H, Shiomi T, et al. Anti - monocyte chemoattractant protein- 1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction [J]. Circulation, 2003,108(17): 2134 - 2140.
  • 8Li H,Simon H,Bocan TM,et al. MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE and MMP- inhibition[J]. Cardiovasc Res ,2000,46(2) :298 - 306.
  • 9Peterson JT, Hallak H, Johnson L, et al. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure[J]. Circulation, 2001,103(18):2303 - 2309.
  • 10Lindsay MM, Maxwell P, Dunn FG. TIMP- 1:a marker of left ventricular diastolic dysfunction and fibrosis in hypertension [ J ].Hypertension ,2002,40(2): 136 - 141.

共引文献19

同被引文献44

  • 1Simonet WS,Lacey DL,Dunstall CR,et al.Osteoprotegerin:a novel secreted protein involved in the regulation of bone density[J].Cell,1997,89(2):309.
  • 2Vidal C,Formosa R,Xuereb-Anastasi A.Functional polymorphisms within the TNFRSF11B(osteoprotegerin)gene increase the risk for low bone mineral density[J].Journal of Molecular Endocrinology,2011,47(3):327-333.
  • 3郏蓉,纪立农.老年人BMD与OPG基因启动子区SNPs及骨代谢生化指标的相关分析研究[D].2011年北京医学会内分泌暨糖尿病学分会学术年会论文集,2011:128-129.
  • 4Roshandel D,Holliday KL,Pye SR,et al.Influence of polymorphisms in the RANKL/RANK/OPG signaling pathway on volumetric bone mineral density and bone geometry at the forearm in men[J].Calcified Tissue International,2011,89(6):446-455.
  • 5Luo Y,Hu Z,Hao J,et al.Significant Associations Between the A163G and G1181C Polymorphisms of the Osteoprotegerin Gene and Risk of Osteoporosis,Especially in Postmenopausal Women:A Meta-Analysis[J].Genetic Testing and Molecular Biomarkers,2014,18(3):211-219.
  • 6Chao TH,Yu HN,Huang CC,et al.Opposite associations of osteoprotegerin and ZBTB40 polymorphisms with bone mineral density of the hip in postmenopausal Taiwan Residents women[J].Journal of the Chinese Medical Association,2012,75(7):335-340.
  • 7Zhang F,He C,Chen G,et al.Association analyses of osteoprotegerin gene polymorphisms withbone mineral density in Chinese postmenopausal women[J].Med Oncol,2013,30(1):389.
  • 8Shen L,Qiu Y,Xing S,et al.Association between osteoprotegerin genetic variants and bone mineral density in Chinese women[J].Int Immunopharmacol,2013,16(2):275-278.
  • 9Wang Q,Chen Z,Huang Y,et al.The relationship between osteoprotegerin gene polymorphisms and bone mineral density in Chinese postmenopausal women[J].Int Immunopharmacol,2013,17(2):404-407.
  • 10Takács I,Lazáryá,Kósa JP,et al.Allelic variations of RANKL/OPG signaling system are related to bone mineral density and in vivo gene expression[J].European Journal of Endocrinology,2010,162(2):423-431.

引证文献2

二级引证文献7

医学临床研究
2014年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部